BrandHistories
Compiling intelligence...
Roche
The acquisition of Foundation Medicine in 2018 for approximately USD 2.4 billion was strategically sound—securing a leading comprehensive genomic profiling platform at a moment when tumour genomics was becoming central to oncology prescribing decisions. However, the integration of Foundation Medicine's clinical laboratory operations with Roche Diagnostics' global commercial infrastructure proceeded more slowly than the strategic rationale warranted, delaying the full realisation of the companion diagnostics synergies that justified the acquisition premium.